Compare Ascendis Pharma A/S (ASND) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Logitech International SA — how do they compare? Ascendis Pharma A/S trades at $264.44 (market cap $17.74B), while Logitech International SA trades at $102.8 (market cap $14.65B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Logitech International SA pays a 1.67% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | LOGI | |
|---|---|---|
Market Cap | $17.74B | $14.65B |
Sector | Health | Technology |
52-Week High | $277.18 | $126.69 |
52-Week Low | $163.32 | $85.84 |
Enterprise Value | $18.11B | $13.00B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Logitech (LOGI) trades at $101.95, up 0.28% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.13 exceeding the $1.10 estimate. Fundamentals show robust profitability, including a 43.2% gross margin and 32.78% ROE, while valuation ratios like P/E of 21.25 and P/S of 3.12 reflect moderate pricing. Recent news highlights partnerships, such as with Call of Duty: Modern Warfare 4, and product launches like the G3 Series, supporting growth momentum.
The outlook for LOGI is cautiously optimistic, with a consensus price target of $113.00 implying 11% upside. Opportunities include B2B expansion and AI-enabled products driving margin growth, but risks involve competitive pressures in peripherals and reliance on consumer spending. Analyst sentiment is divided, with 26% buy ratings balanced by equal sell recommendations, indicating uncertainty amid solid execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
